- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03574402
Phase II Umbrella Study Directed by Next Generation Sequencing (TRUMP)
An Open-label, Multi-center, Phase II Umbrella Study to Assess Efficacy of Targeted Therapy or Immunotherapy Directed by Next Generation Sequencing (NGS) in Chinese Patients With Advanced NSCLC (TRUMP)
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the anti-tumor efficacy of targeted agents or checkpiont inhibitors in advanced stage NSCLC with genomic alteration.
SECONDARY OBJECTIVES:
I. To evaluate the clinical efficacy of targeted agents or checkpiont inhibitors in advanced stage NSCLC with genomic alteration.
II. To evaluate safty and tolerence of targeted agents or checkpiont inhibitors in advanced stage NSCLC with genomic alteration.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Yi-Long Wu, Professor
- Phone Number: 862083827812
- Email: syylwu@live.cn
Study Contact Backup
- Name: Qing Zhou, Dr.
- Phone Number: +8613544561166
- Email: gzzhouqing@126.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Recruiting
- Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology
-
Contact:
- Yi-Long Wu, Professor.
- Phone Number: 862083827812
- Email: syylwu@live.cn
-
Contact:
- Qing Zhou, Dr.
- Email: gzzhouqing@126.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologically or cytologically confirmed, unresectable stage IIIB or stage IV NSCLC
- Patients who have never received any anticancer treatment regimen Note: Patients that have received adjuvant or neoadjuvant chemotherapy and developed metastatic disease after 12 months from the end of that therapy would be eligible for enrollment.
- Measurable disease according to RECIST v.1.1 (Irradiated lesions are not considered measurable unless they have clearly progressed since radiotherapy)
- With or without brain or leptomeningeal metastasis (BM/LM). For patients with symptoms of BM/LM, no need for local therapy should be confirmed by investigator and no dramatic decline of performance status in 2 weeks.
- ECOG performance status ≤ 2
- Expected survival > 12 weeks
- Patients must be suitable and willing to undergo mandatory tumor biopsy according to treating institution's guidelines and requirements for such procedure if there is no archival biopsy available.
- Provision of signed and dated written informed consent by the patient or legally acceptable representative prior to any study-specific procedures.
- Palliative radiotherapy was allowed before enrollment, and radiotherapy-related toxicity grade should no more than 1 (ctcae4.03).
- No anti-tumor Chinese medicine has been used in the past, or has been used for no more than 3 doses, and stopped for more than 2 weeks before enrollment.
- Absolute neutrophil count (ANC) ≥ 1.5x10^9/L without the use of growth factor in the past 14 days. Platelets ≥ 90 × 10^9/L without blood transfusion in the past 14 days. Hemoglobin > 9g/dL.
- Negative pregnancy test (only for women with pregnancy possibility). No possibility of pregnancy defined as at least one year after menopause, or having undergone surgical sterilization or hysterectomy. All patients (male or female) agreed to take contraceptive measures during the treatment and within 8 weeks after the treatment.
Exclusion Criteria:
- Active hepatitis (HBsAg positive and HBV copy number in upper limit of normal)
- Previous or current active interstitial lung disease (ILD)
- Patients known to be HIV positive or with other acquired, congenital immunodeficiency diseases, or with a medical history of organ transplantation.
- Major surgery ≤ 2 weeks prior to study entry.
- Any other malignancies within the last 5 years before study enrollment, except for un completely resected basal cell carcinoma, in situ bladder cancer, cervical carcinoma in situ.
- Patients previously treated with the investigational drugs or known to be allergic to ingredients or excipients of the investigational drugs.
- Pregnant or lactating women.
- Patients with swallowing dysfunction, active gastrointestinal disease or other diseases that significantly affect the absorption, distribution, metabolism and excretion of oral drugs. The patients who have had subtotal gastrectomy before. (this standard is applicable to the arms with oral drugs only)
- Body temperature above 38 ℃ in the past week, or there was active infection with clinical significance. Active tuberculosis;
- Evidence of serious or uncontrollable systemic diseases (such as severe mental, neurological, epilepsy or dementia, unstable or uncompensated respiratory, cardiovascular, liver or kidney diseases, uncontrolled hypertension [higher than CTCAE Level 3 hypertension after drug treatment]);
- Patients with bleeding tendency or taking anticoagulants ;
- There are significant clinical abnormalities in rhythm, conduction or morphology of resting ECG, such as complete left bundle branch block, heart block above degree II, clinically significant ventricular arrhythmia or atrial fibrillation, unstable angina, congestive heart failure, chronic heart failure with NYHA grade ≥ 2.
- Myocardial infarction, coronary / peripheral artery bypass or cerebrovascular accident occurred within 3 months.
- QTc of 12 lead ECG was ≥ 450 ms in male and ≥ 470 ms in female;
- Diagnosed with another malignant disease in the past five years besides NSCLC.
- More than 30% of the bone marrow had received radiotherapy within 4 weeks before treatment.
- Any drugs known to extend QT interval were being used within 2 weeks prior to first administration.
- Strong CYP3A4 inhibitor/inductionor or CYP3A4 substrate were used within 2 weeks, including but not limited to azanavir, clarithromycin, inddenavir, itraconazole, ketoconazole, nefazodone, nefinavir, ritonavir, xaquinavir, talicamycin, acesodamycin, voriconazole, carbamazepine, phenobarbital, phenytoin, rifampin, rifampin, Hypericum perforatum, dihydroergotamine, ergotamine, pimozite, astemizole, cisapride and terfenadine.
- Strong P-gp inhibitor was used within 2 weeks (including but not limited to verapamil, cyclosporine A and right verapamil).
- Other potential risks that are not suitable for the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm1: Avitinib Maleate
Patients with EGFR de novo T790m mutation receive Avitinib 300mg orally (PO) twice daily (BID) on day 1-28.
|
300mg orally (PO) twice daily (BID) on day 1-28.
Other Names:
|
Experimental: Arm2: Chidamide plus Afatinib
Patients with EGFR sensitive mutation with BIM deletion polymorphism receive Afatinib plus Chidamide. Chidamide will be administered 30mg orally twice weekly, 28 days as one cycle. Afatinib will be administered 40mg orally once a day, 28 days as one cycle. |
40mg orally once a day, 28 days as one cycle.
Other Names:
30mg orally twice weekly, 28 days as one cycle.
Other Names:
|
Experimental: Arm3: crizotinib
Patients with MET 14 exon mutation receive crizotinib 250mg PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
250mg PO QD on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm4: X396
Patients with MET amplification receive X396 225mg PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
225mg PO QD on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm5: X396
Patients with ROS1 fusion receive X396 225mg PO QD on days 1-28.
28 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
225mg PO QD on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm6: X396
Patients with Ntrk1/2/3 fusion receive X396 225mg PO QD on days 1-28.
28 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
225mg PO QD on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm7: Pyrotinib Maleate
Patients with HER2 mutation receive Pyrotinib Maleate 400mg PO QD on days 1-28.
28 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
400mg PO QD on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm8: AZD3759
EGFR sensitive mutation with brain/meningeal metastasis receive AZD3759 200mg PO BID on days 1-28.
28 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
200mg PO BID on days 1-28.
28 days as one cycle.
|
Experimental: Arm9: Pirotinib
Patients with EGFR20ins mutation positive receive Pirotinib. This arm was divided into three groups: Group 1, 60mg PO QD on days 1-28. 28 days as one cycle. Group 2, 40mg PO BID on days 1-28. 28 days as one cycle. Group 3, Dosage was determined according to the number of PR patients in Group 2. |
60mg PO QD/40mg PO BID on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm10: Nimotuzumab plus gemcitabine and carboplatin
Lung squamous cell carcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. Gemcitabine 1250mg/m^2, iv gtt. on day 1,8. Carboplatin AUC5, iv gtt. Q3W on day 1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
400mg, iv gtt. on day 1,8,15.
21 days as one cycle.
1g/m^2 iv gtt. on day1,8.
21 days as one cycle.
Other Names:
1.25g/m^2 iv gtt. on day1,8.
21 days as one cycle.
Other Names:
AUC5 iv gtt.
Q3W on day1.
21 days as one cycle.
Other Names:
|
Experimental: Arm11: Nimotuzumab plus pemetrexed and cisplatin
Lung adenocarcinoma with EGFR amplification. Nimotuzumab 400mg, iv gtt. on day 1,8,15. pemetrexed 500mg/m^2, iv gtt. on day 1. Cisplatin 75mg/m^2, iv gtt. Q3W on day 1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
400mg, iv gtt. on day 1,8,15.
21 days as one cycle.
500mg/m^2, iv gtt.
Q3W.
21 days as one cycle.
Other Names:
75mg/m^2, iv gtt.
Q3W on day1.
21 days as one cycle.
Other Names:
|
Experimental: Arm12: Pirotinib
Patients with rare EGFR mutation receive Pirotinib. This arm was divided into two groups: Group 1, 40mg PO BID on days 1-28. 28 days as one cycle. Group 2, Dosage was determined according to the number of PR patients in Group 1. |
60mg PO QD/40mg PO BID on days 1-28.
28 days as one cycle.
Other Names:
|
Experimental: Arm13: Avitinib
Patients with EGFR sensitive mutation receive Avitinib 300mg PO BID on days 1-28.
28 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
300mg orally (PO) twice daily (BID) on day 1-28.
Other Names:
|
Experimental: Arm14: Sintilimab
Patients with PD-L1(TPS)≥50% without EGFR mutation or ALK rearrangement.
Sintilimab 200mg iv gtt.
Q3W on day1.
21 days as one cycle.
Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity.
|
200mg iv gtt.
Q3W on day1.
21 days as one cycle.
|
Experimental: Arm15: Sintilimab
Patients with TMB≥10 mut/Mb,1%≦PD-L1<50% without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
200mg iv gtt.
Q3W on day1.
21 days as one cycle.
|
Experimental: Arm16: Sintilimab
Patients with KRAS and TP53 mutation, 1%≦PD-L1<50%, TMB<10 mut/Mb without EGFR mutation or ALK rearrangement. Sintilimab 200mg iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
200mg iv gtt.
Q3W on day1.
21 days as one cycle.
|
Experimental: Arm17: Sintilimab plus pemetrexed and cisplatin
Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation. Sintilimab 200mg iv gtt. Q3W on day1. Pemetrexedb 500mg/m^2 iv gtt. Q3W on day1. Cisplatin 75mg/m^2 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
500mg/m^2, iv gtt.
Q3W.
21 days as one cycle.
Other Names:
75mg/m^2, iv gtt.
Q3W on day1.
21 days as one cycle.
Other Names:
200mg iv gtt.
Q3W on day1.
21 days as one cycle.
|
Experimental: Arm18: Sintilimab plus Gemcitabine and carboplatin
Patients with PD-L1<1%, TMB<10 mut/mb without EGFR mutation, ALK rearrangement, KRAS or TP53 mutation. Sintilimab 200mg iv gtt. Q3W on day1. Gemcitabine 1g/m^2 iv gtt. on day1,8. Carboplatin AUC5 iv gtt. Q3W on day1. 21 days as one cycle. Courses repeat every 2 cycles in the absence of disease progression or unacceptable toxicity. |
1g/m^2 iv gtt. on day1,8.
21 days as one cycle.
Other Names:
1.25g/m^2 iv gtt. on day1,8.
21 days as one cycle.
Other Names:
AUC5 iv gtt.
Q3W on day1.
21 days as one cycle.
Other Names:
200mg iv gtt.
Q3W on day1.
21 days as one cycle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response rate (RR)
Time Frame: 24 months
|
RECIST version 1.1
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival (PFS)
Time Frame: 24 months
|
RECIST version 1.1
|
24 months
|
Overall survival (OS)
Time Frame: 48 months
|
Overall Survival is defined as the time from first dose to death due to any cause.
Through the follow-up within 30 days after study completion or termination of the last subject, death and date of death will be checked for subject alive during treatment period
|
48 months
|
Disease control rate(DCR)
Time Frame: 24 months
|
RECIST version 1.1
|
24 months
|
Duration of response (DOR)
Time Frame: 24 months
|
RECIST version 1.1
|
24 months
|
Toxicity (number of patients with treatment-related AE as assessed by CTCAE v4.03)
Time Frame: 24 months
|
number of patients with treatment-related AE as assessed by CTCAE v4.03
|
24 months
|
Health-Related Quality of Life (HRQOL)
Time Frame: 24 months
|
EORTC-LC13
|
24 months
|
To explore the mechanism of drug resistance in the treatment of specific gene mutation
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Collaborators
Investigators
- Study Chair: Yi-Long Wu, Guangdong Association of Clinical Trials
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Protein Kinase Inhibitors
- Folic Acid Antagonists
- Gemcitabine
- Carboplatin
- Cisplatin
- Maleic acid
- Pemetrexed
- Ensartinib
- Afatinib
- Crizotinib
- Nimotuzumab
Other Study ID Numbers
- CTONG1702
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Carcinoma, Non-Small-Cell Lung
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Bristol-Myers SquibbCompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung Carcinoma | Non-Squamous Non-Small...United States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Recurrent Lung Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IA...United States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)TerminatedStage IIIA Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingStage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7 | Stage I Lung Non-Small Cell Cancer AJCC v7 | Stage...United States
-
National Cancer Institute (NCI)Active, not recruitingLung Non-Squamous Non-Small Cell Carcinoma | Stage IB Lung Non-Small Cell Carcinoma AJCC v7 | Stage II Lung Non-Small Cell Cancer AJCC v7 | Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIB Lung Non-Small Cell Carcinoma AJCC v7 | Stage IIIA Lung Non-Small Cell Cancer AJCC v7United States, Puerto Rico
-
National Cancer Institute (NCI)Active, not recruitingStage IIIA Lung Non-Small Cell Cancer AJCC v7 | Advanced Lung Non-Squamous Non-Small Cell Carcinoma | Metastatic Lung Non-Squamous Non-Small Cell Carcinoma | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | Stage III Lung Non-Small Cell Cancer AJCC...United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Society of Thoracic RadiologyActive, not recruitingStage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Stage IIA Non-Small Cell Lung Carcinoma | Stage IIB Non-Small Cell Lung Carcinoma | Stage IA Non-Small Cell Lung Carcinoma | Stage IB Non-Small Cell Lung CarcinomaUnited States
Clinical Trials on Avitinib Maleate
-
Sorrento Therapeutics, Inc.Completed
-
Sorrento Therapeutics, Inc.Completed
-
Novartis PharmaceuticalsCompletedAsthmaGermany, United Kingdom
-
National Cancer Institute (NCI)CompletedRecurrent Childhood Medulloblastoma | Recurrent Childhood Ependymoma | Childhood Atypical Teratoid/Rhabdoid Tumor | Childhood Grade I Meningioma | Childhood Grade II Meningioma | Childhood Grade III Meningioma | Childhood Infratentorial Ependymoma | Childhood Supratentorial Ependymoma | Recurrent Childhood... and other conditionsUnited States
-
IlDong Pharmaceutical Co LtdCompleted
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy ParticipantsChina
-
Università degli Studi di FerraraCompleted
-
Rennes University HospitalMinistry of Health, France; Pierre Fabre LaboratoriesCompletedMultiple Sclerosis | Urinary Tract Infections | Bladder DysfunctionFrance
-
National Cancer Institute (NCI)CompletedRecurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Salivary Gland Squamous Cell Carcinoma | Recurrent Lip and Oral Cavity Squamous Cell Carcinoma | Recurrent Nasopharyngeal Keratinizing Squamous... and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedNeurofibromatosis Type 1 | Plexiform Neurofibroma | Spinal Cord NeurofibromaUnited States